Search Results - david+wilson

4 Results

Sort By:

Nanomaterial Vaccine that Activates Tumor Killing Gamma Delta T Cells: A Novel Therapy for Cancer

Value Proposition:· Significant cost savings and time savings compared to standard adoptive T cell therapies· Improved accessibility for patients who cannot reach treatment centers offering adoptive T cell therapies· Direct tumor targeting, limiting systemic clearance and minimizing off-target toxicity.· Increased drug loading ratios...

Published: 3/14/2025 | Inventor(s): David Wilson, Sabrina Chen

Keywords(s):

Category(s): Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Oncology

Polymers and Nanoparticles for Intramuscular Nucleic Acid Delivery

Value Proposition:· Platform technology for prophylactic and therapeutic vaccination with large RNA payloads.· Can deliver several types of nucleic acid payloads including self-amplifying mRNA, plasmid, linear DNA, siRNA, miRNA, mRNA.· Adaptable as a therapeutic delivery strategy for genetic, musculoskeletal, and neurological disorders.Unmet Need:Vaccinology...

Published: 3/14/2025 | Inventor(s): Jordan Green, David Wilson, Stephany Tzeng, Yuan Rui, Sarah Neshat, Kathryn Luly

Keywords(s):

Category(s): Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Infectious Diseases

Polymeric Vaccine for Opioid Addiction

Value Proposition:· Elicits production of anti-Fentanyl antibodies· Leads to long-lasting anti-opioid responses without toxicity· Exhibits 1000-fold increase in antibody production over conventional drug vaccines Technology DescriptionResearchers at Johns Hopkins have developed a polymeric fentanyl vaccine. Upon a primary injection and...

Published: 3/14/2025 | Inventor(s): David Wilson, Sandeep Kumar

Keywords(s):

Category(s): Technology Classifications > Therapeutic Modalities > Vaccines, Clinical and Disease Specializations > Pain, Clinical and Disease Specializations > Psychiatry > Addiction

Gene Delivery Particles to Induce Tumor-Derived Antigen Presenting Cells

Unmet Need Melanoma is an aggressive form of skin cancer that is characterized by high multidrug resistance and low survival rates. The median survival time for metastatic melanoma patients is approximately 8-9 months with a 3-year overall survival rate of less than 15%. As such, there is a compelling need for novel targeted melanoma therapies. Immunotherapy...

Published: 3/14/2025 | Inventor(s): Jordan Green, Stephany Tzeng, David Wilson, Randall Meyer

Keywords(s): Cancers, Disease Indication, Drug Delivery Vehicle, Nanoparticles, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations > Immuno-Oncology, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Immunotherapies